News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
Abbott has recently received the US Food and Drug Administration nod to use its DBS device for treatment-resistant depression
The partnership will accelerate stockpiling, channel distribution and hospital access for the amubarvimab/romlusevimab combination in China
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
Tobacco smoke increases infant morbidity and is fatal to a baby because it damages the baby’s organs
The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction
Subscribe To Our Newsletter & Stay Updated
